Volume 3, Issue 1: European Association for the Study of the Liver (EASL) (/HCV Update)

e-ViralHepatitis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.

 

(Volume 3, Issue 1)

Target Audience

Nurses and health care professionals involved in the care of patients with Hepatitis.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to:      

  • Discuss recent advances for the treatment of HCV genotype 1 infection using peginterferon/ribavirin plus direct acting antivirals (DAAs).
  • Describe recent advances for the treatment of HCV genotype 2 and 3 infection using peginterferon/ribavirin plus direct-acting antivirals (DAAs) and interferon, free oral regimen.
  •  Evaluate emerging interferon-free regimens for the treatment of HCV genotype 1 infection.

 

Additional information
Contact email: 
ijhn@jhmi.edu
Course summary
Available credit: 
  • 1.00 ANCC
Registration opens: 
08/27/2013
Registration closes: 
08/26/2015
Cost:
$0.00

Mark S. Sulkowski, MD

Professor of Medicine

Medical Director, Viral Hepatitis Center

Divisions of Infectious Disease and Gastroenterology/Hepatology

The Johns Hopkins University School of Medicine

Available Credit

  • 1.00 ANCC

Price

Cost:
$0.00
Please login or register to take this course.